The increasing trend of ␤-lactam resistance among Enterobacteriaceae is a worldwide threat. Enterobacteriaceae isolates causing intra-abdominal infections (IAI) from the Study for Monitoring Antimicrobial Resistance Trends (SMART) collected in 2008 and 2009 from the Asia-Pacific region were investigated. Detection of extended-spectrum ␤-lactamases (ESBLs), AmpC ␤-lactamases, and carbapenemases was performed by multiplex PCR. A total of 699 Enterobacteriaceae isolates with positive genotypic results, included Escherichia coli (n ‫؍‬ 443), Klebsiella pneumoniae (n ‫؍‬ 187), Enterobacter cloacae (n ‫؍‬ 45), Klebsiella oxytoca (n ‫؍‬ 9), Citrobacter freundii (n ‫؍‬ 5), Proteus mirabilis (n ‫؍‬ 3), Enterobacter aerogenes (n ‫؍‬ 2), Morganella morganii (n ‫؍‬ 2), and one each of Enterobacter asburiae, Proteus vulgaris, and Providencia rettgeri were analyzed. Nearly 20% of these ␤-lactamase-producing Enterobacteriaceae isolates were from community-associated IAI.
and Thailand (8) . Interspecies plasmid transfer is observed in these bacteria, which further exacerbates public health concerns (1) . Up-to-date epidemiology of antimicrobial resistance surveillance and understanding of the resistance mechanisms are crucial to selection of appropriate treatment for infection.
The Study for Monitoring Antimicrobial Resistance Trends (SMART) monitors the in vitro activities of several antimicrobial agents against Gram-negative aerobic pathogens from intra-abdominal infections (IAI). This program has been ongoing since 2002 in most regions of the world, with nearly 200 hospitals participating in 2012. In this report, we present a comprehensive geographic distribution and genetic analysis of ESBL-, AmpC-, and carbapenemase-producing Enterobacteriaceae isolates collected from the SMART program in the Asia-Pacific region in 2008 and 2009. (This work was presented in part at the Interscience Confer-
RESULTS

Bacterial isolates and distribution of phenotypic resistance.
Overall, 6,510 clinical isolates (of which 5,585 were Enterobacteriaceae) from 34 medical centers in 11 countries located in the AsiaPacific region were collected and tested during the study period. A total of 758 Enterobacteriaceae isolates that either were phenotypically positive for ESBL production or had elevated ertapenem MICs (MIC Ն 0.5 g/ml) were tested for existence of ESBLs, AmpCs, and carbapenemases. The CLSI phenotypic test for ESBL production of E. coli, K. pneumoniae, Klebsiella oxytoca, and Proteus mirabilis was used for all Enterobacteriaceae isolates. All the Enterobacteriaceae species with elevated ertapenem MICs (MIC Ն 0.5 g/ml) were also tested for ESBLs, AmpCs, and carbapenemases by multiplex PCR assay. Ultimately, 699 isolates with ␤-lactamase genes detected in multiplex PCR assay were analyzed, including E. coli (n ϭ 443), K. pneumoniae (n ϭ 187), Enterobacter cloacae (n ϭ 45), K. oxytoca (n ϭ 9), Citrobacter freundii (n ϭ 5), P. mirabilis (n ϭ 3), Enterobacter aerogenes (n ϭ 2), Morganella morganii (n ϭ 2), Enterobacter asburiae (n ϭ 1), Proteus vulgaris (n ϭ 1), and Providencia rettgeri (n ϭ 1). A total of 281 isolates were found with elevated ertapenem MICs (Ն0.5 g/ml), including E. coli (n ϭ 137; 45 with ESBL, 23 with AmpC, and 69 with both ESBL and AmpC), K. pneumoniae (n ϭ 90; 54 with ESBL, 18 with AmpC, and 18 with both ESBL and AmpC), E. cloacae (n ϭ 39; 3 with ESBL, 27 with AmpC, and 9 with both ESBL and AmpC), C. freundii (n ϭ 5; 3 with ESBL and 2 with AmpC), K. oxytoca (n ϭ 4; 2 with ESBL and 2 with both ESBL and AmpC), M. morganii (n ϭ 2 with both ESBL and AmpC), E. aerogenes (n ϭ 1 with ESBL), E. asburiae (n ϭ 1 with both ESBL and AmpC), P. vulgaris (n ϭ 1 with AmpC), and P. rettgeri (n ϭ 1 with AmpC Genotypic distribution of various ␤-lactamases among Enterobacteriaceae causing IAI. In this study, we identified three ESBL types (CTX-M, SHV, and TEM), three AmpC types (CMY, DHA, and ACT/MIR), and three carbapenemase types (NDM, IMP, and OXA) in Enterobacteriaceae isolates causing IAI from the Asia-Pacific area. Table 2 illustrates the distributions of ␤-lactamases in these isolates. HA-IAI isolates had more complicated ␤-lactamase combinations than CA-IAI isolates. The most common ESBLs were CTX-M types (n ϭ 588), followed by SHV (n ϭ 59) and TEM (n ϭ 4). CTX-M-15 and CTX-M-14 were the dominant CTX-M-type ESBLs in Enterobacteriaceae isolates in this study. SHV-12 was the dominant SHV variant for both E. coli and K. pneumoniae isolates. The most common AmpC ␤-lactamase types were CMY (n ϭ 110), followed by DHA (n ϭ 46) and ACT/ MIR (n ϭ 40), in Enterobacteriaceae isolates in this study. CMY-2, DHA-1, and ACT/MIR were the most dominant AmpC-type ␤-lactamases in E. coli, K. pneumoniae, and E. cloacae isolates, respectively. The most common carbapenemases were NDM types (n ϭ 65), followed by IMP (n ϭ 7) and OXA (n ϭ 7). NDM-1 was the most dominant carbapenemase. More than 90% of NDM-1 isolates were HA-IAI isolates (23 of 25 [92%] ). The IMP-and OXA-type carbapenemases were less common, and there were no Klebsiella pneumoniae carbapenemases (KPCs) detected in this study (Table 2) .
Geographic distribution of ESBLs, AmpCs, and carbapenemases. The geographic distribution of ESBLs, AmpCs, and carbapenemases was variable ( (Table 3) .
DISCUSSION
ESBLs are the major cause of resistance to oxyimino-cephalosporins in Enterobacteriaceae (2, 7) . At present, more than 300 different ESBL variants have been described (7) . Most ESBLs can be divided into three groups: TEM, SHV, and CTX-M types. During the past decade, CTX-M-type ESBLs have been increasingly reported, and these enzymes have now replaced TEM and SHV as the most common type of ESBLs in many countries (15) (16) (17) . In line with these reports (15) (16) (17) , our results confirm that CTX-Mtype ESBLs, particularly CTX-M-14 (dominant in China, Taiwan, and South Korea) and CTX-M-15 (dominant in Australia, India, Malaysia, New Zealand, Philippines, Singapore, Thailand, and Vietnam), have become the most prevalent ESBLs in the AsiaPacific region.
Bonnet reported that the presence of the mobile genetic platform ISEcp1 was predominantly found upstream of bla CTX-M-15 , Ertapenem MIC Ͼ 0.5 g/ml Ertapenem MIC Յ 0.5 g/ml Ertapenem MIC Ͼ 0.5 g/ml Ertapenem MIC Յ 0.5 g/ml 
K. pneumoniae with an ertapenem MIC of Յ0.5 g/ml (n ϭ 115) bla CTX-M-9 , and bla CTX-M-14 in CTX-M-producing E. coli isolates that might be involved in both the spread and expression of these genes in Enterobacteriaceae resistance (15) . The spread of bla CTX-M-15 was essentially caused by the clonal expansion of E. coli isolates belonging to the international pandemic ST131 clone (18, 19) , and these strains have been reported to occur in healthy people as a part of the commensal flora (20 K. oxytoca with an ertapenem MIC of Յ0.5 g/ml (n ϭ 5)
Other species with ertapenem MICs of Ͼ0.5 g/ml a (n ϭ 9) (1) Other species with ertapenem MICs of Յ0.5 g/ml a (n ϭ 6) (2) CTX-M-24 (1) a Other species included C. freundii (5), P. mirabilis (3), M. morganii (2) , E. aerogenes (2) , E. asburiae (1), P. vulgaris (1), and P. rettgeri (1) . AmpC ( animals and in river waters, indicating that all ESBLs, not just CTX-M enzymes, could disseminate out of hospitals (21, 22) . In addition, SHV-12 has been reported to be associated with highlevel resistance to ceftazidime in this area (8) . Compatible with a previous report in Thailand (23) , our findings indicate that ESBL genes in the Asia-Pacific region are part of a gene pool capable of broad horizontal gene transfer, in that these genes might transfer between different species of Enterobacteriaceae. AmpC ␤-lactamases are clinically important cephalosporinases encoded on the chromosomes of many of the Enterobacteriaceae, where they mediate resistance to cephalothin, cefazolin, cefoxitin, most penicillins, and ␤-lactamase inhibitors (4) . In many Enterobacteriaceae, AmpC expression is low but inducible in response to ␤-lactam exposure (4, 7) . However, transmissible plasmids for AmpC enzymes, including CMY-2, the most common plasmid-mediated AmpC ␤-lactamase worldwide, could appear in bacteria lacking or poorly expressing chromosomal bla AmpC genes, such as E. coli, K. pneumoniae, and P. mirabilis (24) . In this study, we observed that various types of AmpC ␤-lactamases were found in different Enterobacteriaceae species: CMY-2 in E. coli, DHA-1 in K. pneumoniae, and ACT/MIR in E. cloacae. Recently, plasmids carrying both bla DHA-1 and qnrB, a gene mediating resistance to fluoroquinolones, were observed among isolates of Enterobacteriaceae (25) . Similar to a previous survey in the United States (26), we have shown that AmpC ␤-lactamase production in Enterobacteriaceae isolates frequently coexists with ESBL (n ϭ 128, 66%) or carbapenemase production (n ϭ 43, 22%) in the Asia-Pacific region.
The detection of carbapenemase-producing Enterobacteriaceae strains has been a challenging issue for clinical laboratories. Our results, based on PCR methodology, confirm that the recently lowered CLSI susceptibility breakpoints for carbapenems (11) enhance the classification of carbapenemase producers as nonsusceptible. In this study, based on applying newer ertapenem susceptibility criteria published by the CLSI (11) and PCR analysis, we did not find any KPC-producing Enterobacteriaceae isolates in the SMART 2008 SMART -2009 program in the Asia-Pacific region. Although ESBL-producing Enterobacteriaceae isolates coproducing carbapenemase (10.5% in this study) have not been shown to be major pathogens for IAI, the trends of carbapenem resistance should be carefully monitored.
Our study had the following limitations. First, the numbers of Enterobacteriaceae isolates screened from each country were not equal. The detailed epidemiological information on individual resistance rates and the population coverage of each participant hospital were not disclosed; therefore, selection bias might have existed. Second, we found 59 isolates that were ESBL screen positive but did not have a bla gene identified on the multiplex PCR used. Because the PCR primers of common ␤-lactamases (ESBLs, AmpC ␤-lactamases, and carbapenemases) were prospectively designed, some minor ESBL variants, such as bla VEB , did not have PCR primers in this study. In addition, high ertapenem MICs might also be due to development of active efflux pumps or changes in membrane porins. Third, the CLSI phenotypic confirmation methods (i.e., using ceftazidime or cefotaxime with and without clavulanic acid) are validated only for E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis and may not be adequate for Enterobacter species due to the presence of constitutive chromosomal inducible AmpC ␤-lactamase.
One study suggested that testing with cefepime may be more reliable in detecting the ESBL phenotype in Enterobacter species (27) . Finally, molecular epidemiology, such as pulsed-field gel electrophoresis (PFGE), and highly transmissible mobile genetic elements (ISEcp1) were not studied in this survey. Therefore, the epidemiological relatedness of the multiple-drug-resistant isolates and whether dissemination of resistant lineages (e.g., ST131 E. coli) or interspecies plasmid transfer in these bacteria exacerbates public health concerns in this area need further investigation.
In conclusion, our results reveal the high prevalence of CTX-M-type ESBLs, including CTX-M-14 and CTX-M-15, within many Enterobacteriaceae species in the Asia-Pacific region. Coexistence of plasmid-mediated AmpC ␤-lactamases, such as DHA and CMY, with ESBLs or carbapenemases is common in this region. HA-IAI isolates had more complicated ␤-lactamase combinations than CA-IAI isolates. Although ESBL-producing isolates with relatively low rates of resistance to carbapenems were found in a previous SMART study (8) , we have shown the rapid emergence of NDM-producing isolates in the current SMART study, at least in India. The rapid emergence of multiresistant ESBL-producing Enterobacteriaceae isolates is of major concern and highlights the need for further surveillance in this area. Empirical use of carbapenems for the treatment of IAI should be carefully monitored in countries with higher prevalences of carbapenemaseproducing Enterobacteriaceae.
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